National Guideline Clearinghouse | TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis.

National Guideline Clearinghouse | TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis.

National Institute for Health and Care Excellence (NICE)

• TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. This updates a previously published guideline summary.

Guideline Title

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Feb 1. 70 p. (Technology appraisal guidance; no. 383).

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept and infliximab for ankylosing spondylitis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 47 p. (Technology appraisal guidance; no. 143).

This guideline meets NGC's 2013 (revised) inclusion criteria.